

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Drugs in Development, 2021

<https://marketpublishers.com/r/I802691899A4EN.html>

Date: March 2021

Pages: 63

Price: US\$ 3,500.00 (Single User License)

ID: I802691899A4EN

Abstracts

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Drugs in Development, 2021

SUMMARY

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) pipeline Target constitutes close to 17 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The latest report Islet Amyloid Polypeptide - Drugs in Development, 2021, outlays comprehensive information on the Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Islet amyloid polypeptide (IAPP) or Amylin is a peptide hormone. This hormone is released from pancreatic beta cells following food intake to regulate blood glucose levels and act as a satiation signal. It inhibits insulin-stimulated glucose utilization and glycogen deposition in muscle.

The molecules developed by companies in Phase I, Preclinical and Discovery stages are 2, 10 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Central Nervous System, Gastrointestinal and

Musculoskeletal Disorders which include indications Type 2 Diabetes, Obesity, Type 1 Diabetes (Juvenile Diabetes), Alzheimer's Disease, Diabetes, Non-Alcoholic Steatohepatitis (NASH), Neurodegenerative Diseases, Non Alcoholic Fatty Liver Disease (NAFLD), Osteoarthritis, Pancreatic Diseases and Parkinson's Disease.

Furthermore, this report also reviews key players involved in Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP)

The report reviews Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics and enlists all their major and minor projects

The report assesses Islet Amyloid Polypeptide (Amylin or Diabetes Associated

Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Overview

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Companies Involved in Therapeutics Development

ADM Therapeutics

Adocia SAS

Eli Lilly and Co

Gubra ApS

Neurimmune Holding AG

Nordic Bioscience AS

reMYND NV

Wren Therapeutics Ltd

Zealand Pharma AS

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Drug Profiles

(insulin aspart + pramlintide) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(insulin lispro + pramlintide) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AC-253 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ADM-116 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DACRA-089 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GUI-17 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GUI-35 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KBP-056 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KBP-088 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NI-203 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ReS-39 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit IAPP for Neurodegenerative Diseases and Pancreatic Diseases - Drug Profile

Product Description

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Drug...

Mechanism Of Action

R&D Progress

Synthetic Peptide for Obesity and Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Inhibit ABPP and IAPP for Alzheimer's Disease and Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Target IAPP for Obesity and Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZP-4982 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZP-5461 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Dormant Products

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Discontinued Products

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Product Development Milestones

Featured News & Press Releases

Jun 14, 2019: ADA2019: Find the two Adocia abstracts including the "BioChaperone Glucagon Exenatide" Poster online

Jun 04, 2019: Adocia presents on BioChaperone Pramlintide Insulin at the American Diabetes Association® 79th Scientific Sessions

Feb 12, 2019: Adocia to present new clinical data on Pramlintide-Prandial Insulin combinations at the 12th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2019)

Sep 05, 2018: Adocia announces positive topline results for the first clinical study of BioChaperone Pramlintide Insulin in people with type 1 diabetes

Apr 16, 2018: Adocia initiates First-in-Human Clinical Study of BioChaperone Pramlintide Insulin in people with type 1 diabetes

Apr 03, 2018: Taming an unruly target in diabetes

May 11, 2017: Zealand Pharma discloses amylin as the biological target under their 2014 agreement with Boehringer Ingelheim

Jan 05, 2017: Adocia Launches New Multi-Hormonal Combination Project For Treatment Of Type 1 Diabetes

Jun 08, 2016: Zealand presents new data on proprietary preclinical peptide drug candidates at the 76th Annual American Diabetes Associations Scientific Sessions

May 05, 2014: reMYND's novel diabetes treatment prevents - and even reverses - disease progression in pre-clinical diabetes models

Apr 10, 2013: Centennial Lecture features research on restoring memory and movement

Dec 11, 2012: University Of Alberta Medical Researchers Make Key Discovery In Fight Against Alzheimer's Disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by ADM Therapeutics, 2021
Pipeline by Adocia SAS, 2021
Pipeline by Eli Lilly and Co, 2021
Pipeline by Gubra ApS, 2021
Pipeline by Neurimmune Holding AG, 2021
Pipeline by Nordic Bioscience AS, 2021
Pipeline by reMYND NV, 2021
Pipeline by Wren Therapeutics Ltd, 2021
Pipeline by Zealand Pharma AS, 2021
Dormant Projects, 2021
Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

I would like to order

Product name: Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Drugs in Development, 2021

Product link: <https://marketpublishers.com/r/l802691899A4EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/l802691899A4EN.html>